1q41q42 microdeletion syndrome
one q four one q four two microdeletion syndrome
Also known as: 1q41q42 deletion syndrome, 1q41q42 microdeletion disorder
At a Glance
What is 1q41q42 microdeletion syndrome?
1q41q42 microdeletion syndrome is a rare genetic disorder caused by the deletion of a small piece of chromosome 1. This condition primarily affects the brain, leading to intellectual disabilities and developmental delays. It is caused by a spontaneous genetic mutation, meaning it usually occurs without a family history. Over time, individuals may experience seizures and other neurological issues. Early symptoms often include delayed speech and motor skills, while later symptoms can involve more severe intellectual challenges. Early diagnosis is crucial to provide appropriate interventions and support. The condition can significantly impact family life, requiring ongoing medical care and educational support. Prognosis varies, but many individuals can lead fulfilling lives with the right resources. Daily life may involve therapies and special education to help manage symptoms. Families often need to adapt their routines to accommodate the needs of the affected individual. Support groups and resources can provide valuable assistance. The syndrome is recognized for its distinct clinical features, making it identifiable by specialists.
Medical Definition
1q41q42 microdeletion syndrome is characterized by the deletion of genetic material on chromosome 1, affecting genes such as FBXO28 and WDR26. Pathologically, it involves disruptions in neural development leading to intellectual disabilities and seizures. Histological findings are not typically used for diagnosis, as it is primarily identified through genetic testing. It falls under the classification of chromosomal microdeletion syndromes. Epidemiologically, it is extremely rare, with only a few cases reported worldwide. The disease course is variable, with symptoms ranging from mild to severe, depending on the extent of the deletion.
1q41q42 microdeletion syndrome Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Intellectual disability in 1q41q42 microdeletion syndrome manifests as developmental delays and learning difficulties. This is caused by the deletion of critical genes such as FBXO28, which are involved in neurodevelopment. Over time, the severity can range from mild to severe, impacting educational and social development. Daily life is affected by the need for special education and support services, and early intervention can help maximize potential.
Seizures in this syndrome typically present as recurrent episodes of abnormal electrical activity in the brain. The biological mechanism involves the disruption of neural pathways due to the deletion of genes like FBXO28. Seizures may increase in frequency and severity if not managed properly. They significantly impact daily life, requiring medical management with antiepileptic drugs and regular monitoring.
Developmental delay is characterized by slower achievement of milestones such as walking and talking. It results from the deletion of genes that are crucial for normal brain and physical development. The delay can persist into childhood and adolescence, affecting educational and social skills. Early intervention therapies, including physical and speech therapy, can help improve outcomes.
Common
Hypotonia presents as reduced muscle tone, leading to floppiness and delayed motor skills. This condition arises from neurological impairment due to the genetic deletions. Over time, hypotonia can lead to difficulties with posture and movement. Physical therapy and supportive measures can help improve muscle tone and function.
Facial dysmorphism includes distinct facial features such as a broad forehead and flat nasal bridge. These features result from the developmental impact of the genetic deletions on craniofacial structure. The dysmorphic features are usually present from birth and remain stable over time. While they do not typically affect health, they can impact self-esteem and social interactions.
Behavioral issues may include hyperactivity, aggression, and attention deficits. These arise due to the neurological impact of the microdeletion on brain function. Behavioral problems can become more pronounced with age, affecting social and educational development. Behavioral therapy and structured routines can help manage these challenges.
Less Common
Congenital heart defects can manifest as structural abnormalities of the heart present at birth. These defects are caused by disruptions in the genes responsible for cardiac development. The severity can vary, with some defects requiring surgical intervention. Regular cardiac monitoring and management are essential to prevent complications.
Hearing loss may present as partial or complete inability to hear. It results from the impact of the genetic deletions on auditory system development. Hearing loss can worsen over time, affecting communication and social interactions. Use of hearing aids and early intervention with speech therapy can improve communication skills.
What Causes 1q41q42 microdeletion syndrome?
1q41q42 microdeletion syndrome is primarily associated with deletions affecting the FBXO28 and WDR26 genes located on chromosome 1q41q42. FBXO28 encodes an F-box protein involved in protein ubiquitination, a process crucial for protein degradation and turnover. Mutations or deletions in FBXO28 can lead to impaired ubiquitination, resulting in the accumulation of misfolded or damaged proteins. This disruption can cause cellular stress and interfere with normal cellular functions, particularly in neurons. WDR26, another gene in the region, is involved in signal transduction pathways and its loss can disrupt cellular communication and signaling. The combined loss of these genes affects cellular homeostasis, leading to dysfunction in neuronal pathways and synaptic signaling. Neuroinflammation may be triggered as a response to cellular stress and protein accumulation, exacerbating neuronal damage. The degeneration of white matter and other brain structures occurs due to the cumulative effects of cellular dysfunction and inflammation. Symptoms such as intellectual disability and seizures arise due to the critical role of affected genes in brain development and function. The variability in disease severity among patients may be attributed to the size of the deletion, presence of additional genetic factors, and environmental influences. The specific pattern of symptoms is influenced by the particular genes affected within the deleted region and their roles in neurodevelopment. Additionally, the presence of other modifying genes or compensatory mechanisms can influence the clinical presentation. Understanding the precise molecular mechanisms and pathways affected by these deletions is crucial for developing targeted therapies.
How is 1q41q42 microdeletion syndrome Diagnosed?
Typical age of diagnosis: 1q41q42 microdeletion syndrome is typically diagnosed in early childhood, often when developmental delays or intellectual disabilities become apparent. Diagnosis may occur earlier if there is a known family history or prenatal testing is conducted.
Clinicians look for developmental delays, intellectual disabilities, and distinctive facial features. A detailed family history is important to identify any genetic predispositions. Physical examination may reveal hypotonia, microcephaly, or other dysmorphic features. This step helps determine the need for further genetic testing.
MRI is the preferred imaging modality to assess brain structure. Abnormalities such as corpus callosum agenesis or ventriculomegaly may be visible. These findings support the diagnosis of 1q41q42 microdeletion syndrome. Imaging helps exclude other neurological conditions with similar presentations.
Standard laboratory tests may include metabolic panels to rule out other causes of developmental delay. No specific biomarkers are associated with 1q41q42 microdeletion syndrome. Abnormal results may guide the clinician to consider genetic testing. These tests help exclude metabolic or endocrine disorders.
Chromosomal microarray analysis is used to detect deletions in the 1q41q42 region. Mutations in genes such as FBXO28 and WDR26 are typically found. Positive results confirm the diagnosis and provide information for genetic counseling. This testing is crucial for family planning and understanding recurrence risks.
1q41q42 microdeletion syndrome Treatment Options
Antiepileptic drugs (AEDs) are used to manage seizures associated with the syndrome. These drugs work by stabilizing neuronal membranes and reducing excitability. Common AEDs include valproate and levetiracetam. Clinical evidence supports their efficacy in reducing seizure frequency. Side effects may include drowsiness, dizziness, and potential impacts on cognitive function.
Techniques focus on improving motor skills and muscle tone. The goal is to enhance functional abilities and independence. Sessions are typically conducted weekly and adjusted based on progress. Measurable outcomes include improved coordination and strength. Long-term benefits include better quality of life and reduced disability.
Surgery may be indicated for severe musculoskeletal deformities. Procedures can include tendon releases or spinal corrections. Expected benefits are improved mobility and reduced pain. Surgical risks include infection and anesthesia complications. Post-operative care involves rehabilitation and monitoring for complications.
The team includes neurologists, geneticists, and therapists. Interventions focus on developmental support and seizure management. Psychosocial support is provided through counseling and support groups. Family education covers condition management and resources. Long-term monitoring involves regular assessments and adjustment of care plans.
When to See a Doctor for 1q41q42 microdeletion syndrome
- Severe seizures — immediate medical attention is required as they can lead to life-threatening complications.
- Sudden loss of consciousness — this could indicate a serious neurological event requiring urgent evaluation.
- Difficulty breathing — this is an emergency as it may signal respiratory distress or failure.
- Frequent headaches — could indicate increased intracranial pressure, and a doctor should evaluate this.
- Developmental delays — important to assess for early intervention and management.
- Behavioral changes — may signify neurological or psychological issues that need professional assessment.
- Mild learning difficulties — monitor progress and consult with educational specialists if needed.
- Occasional mood swings — observe for patterns and discuss with a healthcare provider if they worsen.
1q41q42 microdeletion syndrome — Frequently Asked Questions
Is this condition hereditary?
1q41q42 microdeletion syndrome can be hereditary, often following an autosomal dominant pattern. The probability of passing it to children is 50% if a parent carries the deletion. De novo mutations, where the deletion occurs spontaneously, are also common. Carrier status can have implications for family planning and genetic counseling is recommended. Genetic counseling can help families understand inheritance patterns and assess risks.
What is the life expectancy for someone with this condition?
Life expectancy can vary based on the severity of symptoms and associated complications. Early onset of severe symptoms may worsen prognosis, while supportive care can improve outcomes. Mortality is often related to complications such as seizures or respiratory issues. Treatment and management of symptoms can enhance quality of life and potentially extend survival. Realistic expectations should focus on maximizing function and quality of life.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves genetic testing, such as chromosomal microarray analysis, to identify the deletion. The time from first symptoms to diagnosis can vary, often taking months to years. Specialists such as geneticists, neurologists, and developmental pediatricians are usually involved. Delayed diagnosis may occur due to the rarity and variability of symptoms. Confirmation is achieved through genetic testing that identifies the specific chromosomal deletion.
Are there any new treatments or clinical trials available?
Research is ongoing, with promising studies focusing on gene therapy and targeted molecular treatments. Novel approaches aim to address the underlying genetic causes of the syndrome. ClinicalTrials.gov is a resource for finding relevant trials, and discussing options with your doctor is crucial. Patients should inquire about eligibility for trials and potential benefits versus risks. New treatments may take years to become widely available, but ongoing research offers hope.
How does this condition affect daily life and activities?
1q41q42 microdeletion syndrome can impact mobility, self-care, and independence. Educational challenges are common, often requiring specialized support and interventions. Social and emotional difficulties may arise, affecting relationships and mental health. The condition can place a significant burden on families, necessitating comprehensive support systems. Adaptations such as assistive devices and tailored educational programs can significantly enhance quality of life.
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.The discovery of microdeletion syndromes in the post-genomic era: review of the methodology and characterization of a new 1q41q42 microdeletion syndrome.
Shaffer LG, Theisen A, Bejjani BA et al. · Genet Med · 2007 · PMID: 17873649
- 2.Refinement of the critical region of 1q41q42 microdeletion syndrome identifies FBXO28 as a candidate causative gene for intellectual disability and seizures.
Au PY, Argiropoulos B, Parboosingh JS et al. · Am J Med Genet A · 2014 · PMID: 24357076
- 3.ASPP2 deficiency causes features of 1q41q42 microdeletion syndrome.
Zak J, Vives V, Szumska D et al. · Cell Death Differ · 2016 · PMID: 27447114
- 4.New cases and refinement of the critical region in the 1q41q42 microdeletion syndrome.
Rosenfeld JA, Lacassie Y, El-Khechen D et al. · Eur J Med Genet · 2011 · PMID: 20951845
- 5.FBXO28 is a critical gene of the 1q41q42 microdeletion syndrome.
Cassina M, Rigon C, Casarin A et al. · Am J Med Genet A · 2015 · PMID: 25900767
- 6.The crucial role of FBXO28 in the pathogenesis of the 1q41q42 microdeletion syndrome.
Papetti L, Schettini L, Garone G et al. · Am J Med Genet A · 2016 · PMID: 27184008
- 7.Response to: Papetti et al., "The crucial role of FBXO28 in the pathogenesis of the 1q41q42 microdeletion syndrome".
Cassina M · Am J Med Genet A · 2016 · PMID: 27177014
- 8.Phenotypic features of 1q41q42 microdeletion including WDR26 and FBXO28 are clinically recognizable: The first case from Japan.
Yanagishita T, Yamamoto-Shimojima K, Nakano S et al. · Brain Dev · 2019 · PMID: 30635136
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-04-26